Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GKL-006 in Combination With TACE in Unresectable Hepatocellular Carcinoma
NCT07845266Phase 1Completed
- Sponsor
- GenePlus
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of GKL-006 in hepatocellular carcinoma (HCC) (4 arms), sponsored by GenePlus. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose-Limiting Toxicities at 28 days. Started Apr 2024; status: completed.
02
Drugs
GKL-006
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07845266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07845266.